Platelet

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Retrieved on: 
Vendredi, janvier 5, 2024
Patient, Medical Subject Headings, Marketing, Febrile neutropenia, Agency, INN, Fever, Immune system, Risk, Infection, Diffusion, Allergy, DLBCL, ATC, Bone marrow, Cytokine release syndrome, CD20, Platelet, International, Headache, Disease, Neutropenia, Blood, Language, Pleural effusion, Cancer, B-cell lymphoma, Thrombocytopenia, Neutrophil, Rituximab, COVID-19, European Medicines Agency, Select, Bacteria, Anatomy, Anemia, IIA, Sepsis, CD3, Rash, Medical device

Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Columvi, glofitamab, Date of authorisation: 07/07/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Retrieved on: 
Vendredi, janvier 5, 2024
Marketing, Platinum, INN, Risk, HER2, Leukopenia, Heartburn, Woman, BRCA, Man, Nausea, DNA, Cancer, Neoplasm, Mutation, Pancreatic cancer, ADP, Prostate, Anatomy, Cell division, Cough, IIA, Diarrhea, Prostate cancer, HRD, Fatigue, Breast cancer, ATC, Platelet, Pancreas, Prednisone, Disease, Genome, Abdomen, Testosterone, PARP, Neutrophil, Bevacizumab, Appetite, Human, Anemia, Patient, Medical Subject Headings, Peritoneum, International, FIGO, Tubing (recreation), Neutropenia, Language, Castration, Dizziness, Thrombocytopenia, BRCA1, Gene, Tablet, Select, Time, Vomiting, Ovary, Prednisolone, X-ray, Ovarian cancer, Headache, BRCA2, European Medicines Agency, Indigestion, Periodic breathing, Birth control

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Retrieved on: 
Mardi, janvier 2, 2024
Patient, Medical Subject Headings, Marketing, Acute coronary syndrome, Artery, European Commission, Agency, Moyamoya disease, INN, Risk, Platelet, ATC, Myocardial infarction, Bleeding, International, European, Blood, Language, Brain, Heart, Splenic infarction, Vascular disease, European Medicines Agency, Tablet, ADP, Select, Chest pain, Aspirin, Anatomy, Medicine, IIA, Atrial fibrillation, Medical device

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 14, Status: Authorised

Retrieved on: 
Mardi, janvier 2, 2024
Patient, Liver, Medical Subject Headings, Marketing, Survival, INN, Risk, Fever, Caregiver, Spinal muscular atrophy, ATC, SMN2, Platelet, International, Disease, Atrophy, Language, Troponin, SMN1, Thrombocytopenia, Ventilation, European Medicines Agency, Select, Hepatotoxicity, Facial muscles, Safety, Anatomy, Vomiting, IIA, SMA, Medical device

Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 14, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zolgensma, onasemnogene abeparvovec, Date of authorisation: 18/05/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Retrieved on: 
Mardi, janvier 2, 2024
Liver, Medical Subject Headings, Diarrhea, Marketing, European Commission, Stomatitis, Agency, INN, Breast, HER2, Fatigue, Woman, Breast cancer, ATC, Pain, LHRH, International, Platelet, Syringe, European, Injection, Weakness, Nausea, Blood, Language, Neoplasm, Mouth, Cancer, Inflammation, European Medicines Agency, Infection, Growth, Select, Cell, Patient, Liver disease, Time, Anatomy, Medicine, IIA, Birth control

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 5, Status: Authorised

Retrieved on: 
Mardi, janvier 2, 2024
People, Marketing, INN, Risk, Leukopenia, Hypophosphatemia, Hypotension, Pneumonia, Potassium, Nausea, Cancer, Myenteric plexus, Infection, Anatomy, Cough, IIA, Multiple myeloma, Chills, Consciousness, Diarrhea, Fever, Fatigue, Bone marrow, ATC, Pharyngitis, Pain, Platelet, Disease, Nose, Edema, Neutrophil, Speech, Depression, Appetite, Writing, Lymphocyte, Safety, Water, Tachycardia, Anemia, Neurological disorder, Hypocalcemia, Sepsis, Hypokalemia, Patient, Medical Subject Headings, Febrile neutropenia, Lymphocytopenia, Cytokine release syndrome, International, Encephalopathy, Neutropenia, Blood, Language, Thrombocytopenia, Neurotoxicity, Select, Medicine, Vomiting, Upper respiratory tract infection, Headache, Hospital, BCMA, Confusion, European Medicines Agency, Cell, Medical device

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Retrieved on: 
Mardi, janvier 2, 2024
Medical Subject Headings, Marketing, INN, B-cell lymphoma, Infection, ATC, Pharyngitis, Pneumonia, Pain, CD20, Hypertension, Capsule, International, Bleeding, European, Platelet, Disease, Nose, Neutropenia, Language, Mouth, Cancer, Chronic lymphocytic leukemia, Waldenström macroglobulinemia, Thrombocytopenia, Lymphocytosis, Death, Rituximab, CLL, Neutrophil, DSM-IV codes, European Medicines Agency, BTK, Growth, Select, Patient, Bruise, Time, Anatomy, Bone marrow, IIA, Macroglobulinemia, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Brukinsa, zanubrutinib, Date of authorisation: 22/11/2021, Revision: 8, Status: Authorised

IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

Retrieved on: 
Lundi, novembre 20, 2023
Neoplasm, Survival, Șaeș, DRI, IDH, SNO, Cytokine release syndrome, Progression-free survival, MD, NEJM, Clinical trial, Cancer, Infrared spectroscopy correlation table, Cohort, Society, Platelet, GBM, CRS, Cell, Patient, Safety, PFS, Pharmaceutical industry

NEW YORK, Nov. 20, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, presented data demonstrating that all patients treated with INB-200 who completed mandated doses have exceeded a progression-free survival (PFS) of seven months to date. This survival data shows the potential of IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) - genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma (GBM). The poster highlighting the updated clinical data from the Phase 1 INB-200 trial was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting in Vancouver, British Columbia on November 17, 2023.

Key Points: 
  • This survival data shows the potential of IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) - genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma (GBM).
  • All patients receive 1x107 cells per dose, however the number of doses varies depending on the cohort of enrollment.
  • Ten patients have been treated with INB-200: three in Cohort 1 (1 dose), four in Cohort 2 (3 doses) and three in Cohort 3 (6 doses).
  • Preserved gamma-delta T cells found in relapsed tumor 148 days after initial DRI infusion, pointing to durability of gamma-delta T cells in treating cancer.

FibroScan® by Echosens Recognized in AASLD Practice Guidance on Managing Portal Hypertension and Varices in Cirrhosis

Retrieved on: 
Vendredi, novembre 10, 2023
Elastography, Lipinski's rule of five, Dominique, Literature, AASLD, HVPG, Cirrhosis, Liver disease, Mortality, Patient, SSM, Varices, Prognosis, Diagnosis, Decompensation, Chronic liver disease, Platelet, Medical imaging

PARIS and WESTBOROUGH, Mass., Nov. 10, 2023 /PRNewswire/ -- The American Association for the Study of Liver Disease (AASLD) has released new guidance advocating noninvasive tests like FibroScan® for the management of advanced liver disease, including assessment of clinically significant portal hypertension and varices in cirrhosis. This evidence-based approach could impact health outcomes for the majority of asymptomatic patients with this condition.

Key Points: 
  • "Managing portal hypertension in cirrhotic patients is a daily challenge for healthcare professionals," said Jon Gingrich, CEO of Echosens North America .
  • "Given the high mortality rates associated with these conditions, there's an urgent need for effective treatments and early diagnosis.
  • The latest guidance underscores the promise of noninvasive methods for monitoring advanced liver disease patients."
  • This new guidance encapsulates optimal practices for identifying and managing portal hypertension and varices in chronic liver disease.

Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia

Retrieved on: 
Lundi, novembre 6, 2023
Abdominal pain, Headache, Food, Vancouver, Thrombocytopenia, Physician, Health Canada, MD, FRCPC, Hemostasis, Edema, Bleeding, Nausea, Platelet transfusion, Vancouver General Hospital, Chronic liver disease, Risk, Swedish Orphan Biovitrum, ITP, Blood, University, CLD, Woman, Safety, Patient, Hospital, Platelet, Fatigue, Medical imaging, Birth control, Pharmaceutical industry, Avatrombopag, Fever

”The current treatment landscape for immune thrombocytopenia in Canada has left certain patients with limited options.

Key Points: 
  • ”The current treatment landscape for immune thrombocytopenia in Canada has left certain patients with limited options.
  • With today’s approval of Doptelet, patients now have an effective oral treatment option with no food-type restrictions or need for liver function monitoring,” said Dr. Charles H. Li, MD, FRCPC, Consultant Hematologist at Vancouver General Hospital and Clinical Associate Professor at the University of British Columbia.
  • For Sobi Media contacts, click here.
  • Pooled safety data for 128 patients with ITP support the safety and tolerability of DOPTELET.